Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01313650 · ClinicalTrials.gov registry record · Phase 3
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,538
- Enrollment target
NCT01313650 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,538 participants.
The verdict
NCT01313650, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,538 participants
- Enrollment target
Study Summary
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation Powder and Placebo when administered once-daily via a Novel Dry Powder Inhaler over a 24-week treatment period in subjects with COPD. Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to14 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 27 weeks. A subset of subjects at selected sites will also perform 24-hour serial spirometry and Holter monitoring during the study and provide serial blood samples for pharmacokinetic analysis. Sparse pharmacokinetic sampling for population pharmacokinetic analyses will be obtained from non-subset subjects. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) FEV1 on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, clinical laboratory tests, and 24 hour Holter monitoring (subset only).
Interventions
- DRUG Placebo
- DRUG 62.5/25mcg
- DRUG 62.5mcg
- DRUG 25mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,538 participants |
| Start Date | 2011-03-01 |
| Est. Completion | 2012-04-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01313650
The ClinicalTrials.gov registry entry for NCT01313650 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,538 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01313650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01313650 about?
NCT01313650 is a clinical study titled "A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD". This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation Powder and Placebo when administered once-daily via a Novel Dry Powder Inh...
What is the current status of trial NCT01313650?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,538 participants. The study started on 2011-03-01. Estimated completion is 2012-04-05.
What interventions are being tested in trial NCT01313650?
The interventions under investigation include: Placebo (DRUG), 62.5/25mcg (DRUG), 62.5mcg (DRUG), 25mcg (DRUG).
Who is sponsoring clinical trial NCT01313650?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.